Targeting c-Met in the treatment of urologic neoplasms: Current status and challenges

At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and dru...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1071030
Main Authors Su, Pengxiao, Zhang, Ming, Kang, Xin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 07.03.2023
Subjects
bladder cancer
c-Met
HGF
Oncology
prostate cancer
renal cell carcinoma
urologic neoplasms
tyrosine kinase inhibitors
prostate cancer
renal cell carcinoma
CAR-T
HGF
bladder cancer
urologic neoplasms
c-Met
Online AccessGet full text

Cover

More Information
Summary:At present, studies have found that c-Met is mainly involved in epithelial-mesenchymal transition (EMT) of tumor tissues in urologic neoplasms. Hepatocyte growth factor (HGF) combined with c-Met promotes the mitosis of tumor cells, and then induces motility, angiogenesis, migration, invasion and drug resistance. Therefore, c-Met targeting therapy may have great potential in urologic neoplasms. Many strategies targeting c-Met have been widely used in the study of urologic neoplasms. Although the use of targeting c-Met therapy has a strong biological basis for the treatment of urologic neoplasms, the results of current clinical trials have not yielded significant results. To promote the application of c-Met targeting drugs in the clinical treatment of urologic neoplasms, it is very important to study the detailed mechanism of c-Met in urologic neoplasms and innovate c-Met targeted drugs. This paper firstly discussed the value of c-Met targeted therapy in urologic neoplasms, then summarized the related research progress, and finally explored the potential targets related to the HGF/c-Met signaling pathway. It may provide a new concept for the treatment of middle and late urologic neoplasms.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Massimo Broggini, Mario Negri Institute for Pharmacological Research, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Italy
Reviewed by: Xin Xu, Zhejiang University, China; Rodolfo Hurle, Humanitas Research Hospital, Italy
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1071030